tqb2450
Showing 1 - 21 of 21
Advanced Squamous Non-Small Cell Lung Carcinoma Trial in Beijing, Tianjin, Kunming (TQB2450, Anlotinib HCl capsule, Tislelizumab
Not yet recruiting
- Advanced Squamous Non-Small Cell Lung Carcinoma
- TQB2450
- +2 more
-
Beijing, Beijing, China
- +3 more
Feb 12, 2023
Stage II-IIIB(N2) NSCLC Trial in Shanghai (TQB2450, Carboplatin, Pemetrexed)
Not yet recruiting
- Stage II-IIIB(N2) Non-small Cell Lung Cancer
- TQB2450
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Oct 26, 2023
Esophageal Squamous Cell Carcinoma, Esophageal Tumors, Esophageal Diseases Trial (Anlotinib HCl, TQB2450)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- +10 more
- Anlotinib hydrochloride
- TQB2450
- (no location specified)
Feb 19, 2022
Gastric Cancer, Gastroesophageal-junction Cancer Trial (IBI315, Oxaliplatin, Capecitabine)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- IBI315
- +5 more
- (no location specified)
Nov 2, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (TQB2450, Intensity modulated radiotherapy)
Recruiting
- Nasopharyngeal Carcinoma
- TQB2450
- Intensity modulated radiotherapy
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Hospital
Jun 16, 2021
Stage III Non-small-cell Lung Cancer Trial in China (TQB2450, Anlotinib, TQB2450(blank))
Recruiting
- Stage III Non-small-cell Lung Cancer
- TQB2450
- +3 more
-
Hefei, Anhui, China
- +35 more
Mar 15, 2022
Small-cell Lung Cancer Trial in Shanghai (TQB2450)
Recruiting
- Small-cell Lung Cancer
- TQB2450
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Jan 25, 2021
Recurrent or Metastatic Cervical Cancer Trial in Jinan (TQB2450)
Not yet recruiting
- Recurrent or Metastatic Cervical Cancer
- TQB2450
-
Jinan, Shangdong, ChinaQilu Hospital of Shandong University
Nov 9, 2020
Safety and Effectiveness Trial in Beijing (TQB2450)
Unknown status
- Safety and Effectiveness
- TQB2450
-
Beijing, ChinaNo.17, panjiayuan nanli, chaoyang district, Beijing
Oct 8, 2020
Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL) Trial in China (TQB2450)
Terminated
- Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
- TQB2450
-
Beijing, Beijing, China
- +17 more
Jan 21, 2021
Advanced Oligometastatic NSCLC Trial in Beijing, Shanghai, Tianjin (TQB2450, SBRT)
Not yet recruiting
- Advanced Oligometastatic Non-small Cell Lung Cancer
- TQB2450
- SBRT
-
Beijing, Beijing, China
- +3 more
Mar 12, 2020
Advanced Renal Cancer Trial in China (TQB2450, Anlotinib, Sunitinib)
Recruiting
- Advanced Renal Cancer
- TQB2450
- +2 more
-
Hefei, Anhui, China
- +25 more
Sep 9, 2020
Advanced Solid Tumors Trial in Chang chun (TQB2450, Anlotinib)
Unknown status
- Advanced Solid Tumors
- TQB2450
- Anlotinib
-
Chang chun, Jilin, ChinaJilin Cancer Hospital
Oct 29, 2019
Advanced Cholangiocarcinoma Trial in Beijing (Anlotinib, TQB2450)
Unknown status
- Advanced Cholangiocarcinoma
- Anlotinib
- TQB2450
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Oct 29, 2019
Advanced Acral Malignant Melanoma Trial in Beijin (Anlotinib, TQB2450)
Unknown status
- Advanced Acral Malignant Melanoma
- Anlotinib
- TQB2450
-
Beijin, Beijing, ChinaBeijing Cancer Hospital
Oct 29, 2019
NSCLC Trial in Lanzhou, Luoyan, Changchun (TQB2450, Anlotinib)
Unknown status
- Non-small Cell Lung Cancer
- TQB2450
- Anlotinib
-
Lanzhou, Gansu, China
- +2 more
Oct 29, 2019
Extensive Small Cell Lung Cancer Trial in China (TQB2450, Anlotinib, Etoposide)
Not yet recruiting
- Extensive Small Cell Lung Cancer
- TQB2450
- +5 more
-
Bengbu, Anhui, China
- +25 more
Jan 18, 2020
Lung Cancer Trial in Guangzhou (TQB2450, Anlotinib)
Unknown status
- Lung Cancer
- TQB2450
- Anlotinib
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 13, 2019
Tumor Trial (TQB2450)
Unknown status
- Tumor
- TQB2450
- (no location specified)
Mar 2, 2018